Praeruptorin D
CAS: 73069-28-0
Ref. 3D-FP73862
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen |
Produktinformation
- (+) Pareruptorin B
- (+)-Anomalin
- (+)-Praeruptorin B
- 2-Butenoic acid, 2-methyl-, (9S,10S)-9,10-dihydro-8,8-dimethyl-2-oxo-2H,8H-benzo[1,2-b:3,4-b′]dipyran-9,10-diyl ester, (2Z,2′Z)-
- 2-Butenoic acid, 2-methyl-, 9,10-dihydro-8,8-dimethyl-2-oxo-2H,8H-benzo[1,2-b:3,4-b′]dipyran-9,10-diyl ester, [9S-[9α(Z),10α(Z)]]-
- 2H,8H-Benzo[1,2-b:3,4-b′]dipyran, 2-butenoic acid deriv.
- 8,8-Dimethyl-2-oxo-2,8,9,10-tetrahydropyrano(2,3-f)chromene-9,10-diyl bis((Z)-2-methyl-2-butenoate)
- Pd II
- Pdii
Praeruptorin D is a salivianolic compound that has been shown to inhibit the production of tumour necrosis factor-α (TNF-α) in vitro. In vivo, it has also been shown to decrease the number of leukocytes and polymorphonuclear cells in the lungs of rats with acute lung injury. The pharmacokinetic study showed that praeruptorin D is metabolized by human cytochrome P450 enzymes, which may explain its low bioavailability and short half-life. This drug has been shown to be effective as an adjuvant therapy for life-threatening infections caused by Gram-negative bacteria and is also active against Mycobacterium tuberculosis, Mycobacterium avium complex, Staphylococcus aureus, and Streptococcus pneumoniae.